Immunotherapy of Cancer
Author:
- John R. DurantJDJohn R. Durant
- 9 April 1987
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 316 (15) , 939-941
Abstract
This issue of the Journal includes reports by two different groups of investigators concerning their experience with adoptive immunotherapy for cancer.1 , 2 A total of 48 responses (8 complete, 28 partial, and 12 minor) are reported among 146 patients (of the 156 who were entered) treated with a variety of doses and schedules of interleukin-2 and lymphokine-activated killer (LAK) cells. Among 46 evaluable patients (of 49 entered) who received the highest tolerable doses of interleukin-2 alone, seven responses (one complete, five partial, and one minor) are reported.Since the first 25 patients treated with interleukin-2 and LAK cells were described in . . .Keywords
This publication has 8 references indexed in Scilit:
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated CancerJAMA, 1986
- On Lymphokines, Cytokines, and Breakthroughs1986
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma.Proceedings of the National Academy of Sciences, 1985
- Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype AntibodyNew England Journal of Medicine, 1982